The Apex Times
Above the Noise
Business Wire
BusinessBrent nears $89 as Hormuz remains disrupted, while Chevron joins Exxon and Shell in “record cash flow” pushThe Apex TimesBusinessGerber Kawasaki’s Ross Gerber tells investors iPhone demand is holding up even as Apple raises pricesThe Apex TimesBusinessFedEx shares face a valuation debate after regional job cuts, but a discounted-cash-flow model suggests deeper upside than the tapeThe Apex TimesBusinessNvidia and major Wall Street firms plan to funnel $500 billion-plus into AI data centers, a bet on demand for chipsThe Apex TimesBusinessDan Niles tells investors AI infrastructure spending may stay strong for at least a year, calls Intel his preferred chip exposureThe Apex TimesBusinessElon Musk Touts Tesla’s U.S. Manufacturing as Auto Tariffs Roil the IndustryThe Apex TimesBusinessBroadcom shares bounce after sharp dip, as retail traders weigh VMware risks ahead of next earningsThe Apex TimesBusinessGoldman Sachs warns markets are pricing Federal Reserve rate hikes too aggressivelyThe Apex TimesBusinessTarget shares jump as multiple Wall Street firms lift price targets ahead of fiscal Q2 resultsThe Apex TimesBusinessPalantir investors grapple with a 2030 question: how long can growth and demand hold?The Apex TimesBusinessWarner Bros. Discovery director trims nearly 70% of stake in roughly $2 million sale as Paramount Skydance deal draws scrutinyThe Apex TimesBusinessToyota’s “Energy Crisis” episode spotlights Japan’s push for electrification and alternative fuels as shipping costs riseThe Apex TimesBusinessBrent nears $89 as Hormuz remains disrupted, while Chevron joins Exxon and Shell in “record cash flow” pushThe Apex TimesBusinessGerber Kawasaki’s Ross Gerber tells investors iPhone demand is holding up even as Apple raises pricesThe Apex TimesBusinessFedEx shares face a valuation debate after regional job cuts, but a discounted-cash-flow model suggests deeper upside than the tapeThe Apex TimesBusinessNvidia and major Wall Street firms plan to funnel $500 billion-plus into AI data centers, a bet on demand for chipsThe Apex TimesBusinessDan Niles tells investors AI infrastructure spending may stay strong for at least a year, calls Intel his preferred chip exposureThe Apex TimesBusinessElon Musk Touts Tesla’s U.S. Manufacturing as Auto Tariffs Roil the IndustryThe Apex TimesBusinessBroadcom shares bounce after sharp dip, as retail traders weigh VMware risks ahead of next earningsThe Apex TimesBusinessGoldman Sachs warns markets are pricing Federal Reserve rate hikes too aggressivelyThe Apex TimesBusinessTarget shares jump as multiple Wall Street firms lift price targets ahead of fiscal Q2 resultsThe Apex TimesBusinessPalantir investors grapple with a 2030 question: how long can growth and demand hold?The Apex TimesBusinessWarner Bros. Discovery director trims nearly 70% of stake in roughly $2 million sale as Paramount Skydance deal draws scrutinyThe Apex TimesBusinessToyota’s “Energy Crisis” episode spotlights Japan’s push for electrification and alternative fuels as shipping costs riseThe Apex TimesBusinessBrent nears $89 as Hormuz remains disrupted, while Chevron joins Exxon and Shell in “record cash flow” pushThe Apex TimesBusinessGerber Kawasaki’s Ross Gerber tells investors iPhone demand is holding up even as Apple raises pricesThe Apex TimesBusinessFedEx shares face a valuation debate after regional job cuts, but a discounted-cash-flow model suggests deeper upside than the tapeThe Apex TimesBusinessNvidia and major Wall Street firms plan to funnel $500 billion-plus into AI data centers, a bet on demand for chipsThe Apex TimesBusinessDan Niles tells investors AI infrastructure spending may stay strong for at least a year, calls Intel his preferred chip exposureThe Apex TimesBusinessElon Musk Touts Tesla’s U.S. Manufacturing as Auto Tariffs Roil the IndustryThe Apex TimesBusinessBroadcom shares bounce after sharp dip, as retail traders weigh VMware risks ahead of next earningsThe Apex TimesBusinessGoldman Sachs warns markets are pricing Federal Reserve rate hikes too aggressivelyThe Apex TimesBusinessTarget shares jump as multiple Wall Street firms lift price targets ahead of fiscal Q2 resultsThe Apex TimesBusinessPalantir investors grapple with a 2030 question: how long can growth and demand hold?The Apex TimesBusinessWarner Bros. Discovery director trims nearly 70% of stake in roughly $2 million sale as Paramount Skydance deal draws scrutinyThe Apex TimesBusinessToyota’s “Energy Crisis” episode spotlights Japan’s push for electrification and alternative fuels as shipping costs riseThe Apex TimesBusinessBrent nears $89 as Hormuz remains disrupted, while Chevron joins Exxon and Shell in “record cash flow” pushThe Apex TimesBusinessGerber Kawasaki’s Ross Gerber tells investors iPhone demand is holding up even as Apple raises pricesThe Apex TimesBusinessFedEx shares face a valuation debate after regional job cuts, but a discounted-cash-flow model suggests deeper upside than the tapeThe Apex TimesBusinessNvidia and major Wall Street firms plan to funnel $500 billion-plus into AI data centers, a bet on demand for chipsThe Apex TimesBusinessDan Niles tells investors AI infrastructure spending may stay strong for at least a year, calls Intel his preferred chip exposureThe Apex TimesBusinessElon Musk Touts Tesla’s U.S. Manufacturing as Auto Tariffs Roil the IndustryThe Apex TimesBusinessBroadcom shares bounce after sharp dip, as retail traders weigh VMware risks ahead of next earningsThe Apex TimesBusinessGoldman Sachs warns markets are pricing Federal Reserve rate hikes too aggressivelyThe Apex TimesBusinessTarget shares jump as multiple Wall Street firms lift price targets ahead of fiscal Q2 resultsThe Apex TimesBusinessPalantir investors grapple with a 2030 question: how long can growth and demand hold?The Apex TimesBusinessWarner Bros. Discovery director trims nearly 70% of stake in roughly $2 million sale as Paramount Skydance deal draws scrutinyThe Apex TimesBusinessToyota’s “Energy Crisis” episode spotlights Japan’s push for electrification and alternative fuels as shipping costs riseThe Apex Times
Back to front
Goldman Sachs reported to have increased positions in CAPR, SLS and IBRX, with Sellas stake valued at about $8.6 million
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 17, 2:15 AM EDT

Goldman Sachs reported to have increased positions in CAPR, SLS and IBRX, with Sellas stake valued at about $8.6 million

A market update says Goldman Sachs boosted its holdings in Sellas by 5.2%, and also built exposure across two additional biotech names, as investors watch potential catalysts for the companies.

3 min readEditor-approved Apex article

Goldman Sachs has reportedly increased its exposure to three smaller biotechnology stocks, according to a market update that highlights new positioning in Capricor Therapeutics (CAPR), Sellas Life Sciences (SLS), and ImmunityBio (IBRX). The post frames the activity as part of a broader set of bets that could become more meaningful if upcoming company-specific catalysts play out.

In the clearest figure cited, Goldman Sachs increased its stake in Sellas by 5.2%, moving to 585,035 shares. The same report estimates the position’s value at $8.64 million, putting a dollar amount behind the change rather than leaving it as a purely directional claim.

The update also indicates that Goldman built additional exposure in CAPR and IBRX, positioning the move as a cross-portfolio rotation rather than a single-stock decision. However, the post does not provide the size of the changes for those two tickers in the information available here, so the extent of the build in each name cannot be independently quantified from the material presented.

Sellas, Capricor, and ImmunityBio are all small-cap, event-driven biotechnology companies where investor sentiment and liquidity can swing on trial readouts, regulatory milestones, and partner updates. In that kind of setup, large market-makers and institutional investors may adjust positions quickly as new information emerges, even if the firm does not comment publicly on the motives for each trade.

Goldman Sachs, as a major global investment bank and asset manager, is an active participant in equity markets and often holds positions through a range of strategies. In cases like this, reported changes in share counts can reflect a mix of trading, hedging, and longer-term allocation decisions, and the market may interpret them as indicates about what catalysts investors should watch.

Still, the report’s emphasis on “major catalysts” is not paired with specific dates or descriptions of what those catalysts are for each company. Without those details, readers are left to infer that the cited names may have upcoming milestones, but the information provided does not identify the events or the timing.

For investors and analysts tracking these moves, the most immediate datapoint is the Sellas position size and estimated value, since the report gives both a share count and an attributed dollar valuation. The remaining two tickers are mentioned, but with less disclosure about how many shares changed or what the estimated values are, making it difficult to compare relative exposure across the three names.

Looking ahead, the key developments to watch are any company announcements or trial updates tied to the implied catalysts, along with any further disclosure on Goldman’s positions. If additional filings or credible market tracking shows updated share counts for CAPR and IBRX, it would help determine whether the reported builds were modest adjustments or larger re-risking decisions.

Why It Matters

  • Reported position changes by a large institution can influence attention and liquidity around small-cap biotech names, especially when investors are focused on near-term milestones.
  • If the catalysts referenced in the update relate to meaningful clinical or regulatory events, the timing of those announcements could affect how markets interpret Goldman’s exposure.
  • Because the post provides detailed figures only for Sellas, readers may not be able to gauge Goldman’s relative risk across the three biotech stocks without additional disclosure.
  • The activity underscores how event-driven biotech trading can attract capital from sophisticated market participants, even when outcomes remain uncertain.

Sources

Key Facts

  • A market update says Goldman Sachs increased holdings across CAPR, SLS, and IBRX.
  • For Sellas Life Sciences (SLS), the post says Goldman increased its stake by 5.2% to 585,035 shares.
  • The post estimates the Sellas stake at $8.64 million.
  • The update suggests the moves are tied to upcoming “major catalysts,” but it does not specify what those catalysts are.
  • No share-count changes or estimated values are provided for CAPR and IBRX within the available information.

Finance Related

Goldman Sachs reported to have increased positions in CAPR, SLS and IBRX, with Sellas stake valued at about $8.6 million | The Apex Times